Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic non small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT06228482
Phase
PHASE1
Sponsor
University of California, Davis
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.
Locations (sample)
  • Sacramento, California, United States|38.58157,-121.4944

Key Eligibility Criteria

  • \[68Ga\]Ga DOTA-5G PET/CT Inclusion Criteria:
  • Ability to understand and willingness to sign a written informed consent document.
  • Age 18 or more years
  • Pathologically confirmed NSCLC with metastatic disease and measurable disease per RECIST (version 1.1) (i.e. at least 1 lesion \> 1 cm or lymph nod…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →